Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

663
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
663
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

922
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
922
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Person-centered intervention response in primary progressive aphasia: A secondary analysis of the Communication Bridge-2 randomized clinical trial.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Tau topography subtypes account for clinical heterogeneity and longitudinal trajectories in early-onset Alzheimer's disease.

Brain communications·2026
Same author

Cognitive dispersion profiles and prediction of cognitive change in early-onset dementias: Results from LEADS.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Criterion and convergent validity of plasma biomarkers in early-onset Alzheimer's disease: Initial findings from LEADS.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Associations between greenspace and memory: Evidence from the COMPASS cohort in Chicago.

Environmental research·2026
Same author

Psychometric criteria for superior cognitive performance in very old adults.

Journal of Alzheimer's disease : JAD·2026

Related Experiment Video

Updated: Mar 31, 2026

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

18.5K

Thinking Outside the Stroke: Treating Primary Progressive Aphasia (PPA).

Becky Khayum1, Christina Wieneke1, Emily Rogalski1

  • 1Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Chicago, IL.

Perspectives on Gerontology
|October 27, 2015
PubMed
Summary

Primary Progressive Aphasia (PPA) is a neurodegenerative condition where language abilities progressively decline. Speech therapy aims to maximize communication and quality of life for individuals with PPA.

More Related Videos

Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia
08:48

Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia

Published on: May 6, 2016

13.0K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.5K

Related Experiment Videos

Last Updated: Mar 31, 2026

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

18.5K
Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia
08:48

Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia

Published on: May 6, 2016

13.0K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.5K

Area of Science:

  • Neurology
  • Speech-Language Pathology

Background:

  • Primary Progressive Aphasia (PPA) is a neurodegenerative disorder characterized by progressive language decline.
  • Unlike recovery from stroke or brain injury, PPA involves worsening language and emergent symptoms, impacting lifespan.

Purpose of the Study:

  • To explore symptoms, causes, treatment potential, and supportive services for individuals with PPA.
  • To provide speech-language pathologists with information and tools to aid PPA patients.
  • To enhance communication and quality of life for those living with PPA.

Main Methods:

  • Review of current literature on PPA symptoms and progression.
  • Analysis of speech therapy approaches for maximizing communication in PPA.
  • Identification of supportive services for PPA patients and their families.

Main Results:

  • PPA is distinct from other neurological conditions due to its progressive nature and focus on language deterioration.
  • Speech therapy for PPA prioritizes functional communication over language restoration.
  • Comprehensive support services are crucial for managing PPA and improving patient well-being.

Conclusions:

  • Effective management of PPA involves tailored speech therapy and supportive services.
  • Maximizing communication is the primary goal to improve the quality of life for individuals with PPA.
  • Further research into PPA causes and treatments is warranted.